pharma · Acquired Blepharoptosis · Diabetic Macular Edema
Santen Oy
SANTEN OY is a pharma organization headquartered in TAMPERE, FI. Primary therapeutic focus areas include Acquired Blepharoptosis, Diabetic Macular Edema, Fuchs Endothelial Corneal Dystrophy (FECD). NovaPharmaNews links 3
TAMPERE, FI HQ
15 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- TAMPERE, FI
- Employees
- 15
- Programs
- 3
- Drugs
- 8
- Patents
- 0
101090401IN
Phase 2 · small molecule · Fuchs Endothelial Corneal Dystrophy (FECD)
101090401IN for Fuchs Endothelial Corneal Dystrophy (FECD) is a Phase 2 program (small_molecule) at Santen Oy with 1 ClinicalTrials.gov record(s).
Internal code 101090401IN
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Santen Oy
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Fuchs Endothelial Corneal Dystrophy (FECD)
- Status
- active
- Trials
- 1